Experiment 1304010
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Salix alba (SALICACEAE) |
| Citation | SHRIVASTAVA,R: PECHADRE,JC: JOHN,GW:. (2006). TANACETUM PARTHENIUM AND SALIX ALBA (MIG-RL) COMBINATION IN MIGRAINE PROPHYLAXIS: A PROSPECTIVE, OPEN-LABEL STUDY. 26(5) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PROSPECTIVE, OPEN-LABEL STUDY WAS PERFORMED IN 12 PATIENTS DIAGNOSED WITH MIGRAINE WITHOUT AURA. TWELVE WEEKS' TREATMENT WITH TANACETUM PARTHENIUM 300 MG PLUS SALIX ALBA 300 MG (MIG-RL) TWICE DAILY WAS ADMINISTERED TO DETERMINE THE EFFECTS OF THERAPY ON MIGRAINE ATTACK FREQUENCY (PRIMARY EFFICACY CRITERION), INTENSITY AND DURATION (SECONDARY EFFICACY CRITERIA), AND QUALITY OF LIFE, TOGETHER WITH TOLERABILITY FOR PATIENTS. ATTACK FREQUENCY WAS REDUCED BY 57.2% AT 6 WEEKS (P < 0.029) AND BY 61.7% AT 12 WEEKS (P < 0.025) IN NINE OF TEN PATIENTS, WITH 70% PATIENTS HAVING A REDUCTION OF AT LEAST 50%. ATTACK INTENSITY WAS REDUCED BY 38.7% AT 6 WEEKS (P < 0.005) AND BY 62.6% AT 12 WEEKS (P < 0.004) IN TEN OF TEN PATIENTS, WITH 70% OF PATIENTS HAVING A REDUCTION OF AT LEAST 50%. ATTACK DURATION DECREASED BY 67.2% AT 6 WEEKS (P < 0.001) AND BY 76.2% AT 12 WEEKS (P < 0.001) IN TEN OF TEN PATIENTS. SELF-ASSESSED GENERAL HEALTH, PHYSICAL PERFORMANCE, MEMORY AND ANXIETY ALSO IMPROVED BY THE END OF THE STUDY. MIG-RL TREATMENT WAS WELL TOLERATED AND NO ADVERSE EVENTS OCCURRED. |
| Dose amount | 300 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | PLANT |
| Gender | GIVEN TO BOTH SEXES |